Der Ophthalmologe

, Volume 108, Issue 1, pp 7–12 | Cite as

Biologika

„Magic bullets – magic effects – magic costs“? Neue Therapien und ihre (Aus-)Wirkungen
Leitthema
  • 212 Downloads

Zusammenfassung

Biologika und insbesondere therapeutische monoklonale Antikörper haben in den letzten Jahren einen regelrechten Siegeszug in der Therapie von entzündlichen und malignen Erkrankungen angetreten. Sie ermöglichen eine zielgerichtete Blockade von Zytokinen, Rezeptoren und anderen Moleküle. Die folgende Übersichtsarbeit skizziert die immunologischen Grundlagen, den gegenwärtigen Entwicklungsstand sowie zukünftige Entwicklungen dieser Therapeutika.

Schlüsselwörter

Biologika Monoklonale Antikörper Rezeptoren Entzündung Zytokine 

Biologics

Magic bullets – magic effects – magic costs? New therapeutics and their effects

Abstract

Biologics and especially therapeutic monoclonal antibodies have an ever increasing impact in the therapy of inflammatory and malignant diseases. They allow a selective blockade of cytokines, receptors and other molecules. This review summarizes the immunological background, the current state and future trends in the development of these therapeutic agents.

Keywords

Biologics Monoclonal antibodies Receptors Inflammation Cytokines 

Literatur

  1. 1.
    Aggarwal S (2009) What’s fueling the biotech engine – 2008. Nat Biotechnol 27(11):987–993CrossRefPubMedGoogle Scholar
  2. 2.
    Glaeske G, Schicktanz C (2010) BARMER GEK Arzneimittel-Report 2010, vol. Band 2. Asgard-Verlag, St. AugustinGoogle Scholar
  3. 3.
    Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497CrossRefPubMedGoogle Scholar
  4. 4.
    Reichert JM (2008) Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 9(6):423–430CrossRefPubMedGoogle Scholar
  5. 5.
    Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10(5):301–316CrossRefPubMedGoogle Scholar
  6. 6.
    Williams-Skipp C, Raman T, Valuck RJ et al (2009) Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum 60(2):408–418CrossRefPubMedGoogle Scholar
  7. 7.
    Bluml S, Binder NB, Niederreiter B et al (2010) Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum 62(6):1608–1619CrossRefPubMedGoogle Scholar
  8. 8.
    Isaacs JD (2010) The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 10(8):605–611CrossRefPubMedGoogle Scholar
  9. 9.
    Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028CrossRefPubMedGoogle Scholar
  10. 10.
    Strangfeld A, Hierse F, Kekow J et al (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68(12):1856–1862CrossRefPubMedGoogle Scholar
  11. 11.
    Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345–352CrossRefPubMedGoogle Scholar
  12. 12.
    Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941–4944CrossRefPubMedGoogle Scholar
  13. 13.
    Schellekens H, Moors E (2010) Clinical comparability and European biosimilar regulations. Nat Biotechnol 28(1):28–31CrossRefPubMedGoogle Scholar
  14. 14.
    Sack U, Emmrich F (2008) Monoclonal antibodies. Principles, generation, application, and side effects. Internist (Berl) 49(8):919–928Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Institut für ImmunologieUniversitätsklinikum JenaJenaDeutschland

Personalised recommendations